Paxman announces multi centre FDA trial for the prevention of chemotherapy induced al

[News]

Paxman, the leading global expert and supplier in scalp cooling for cancer chemotherapy patients, has been granted Investigational Device Exemption (IDE) Approval by the U.S. Food and Drug Administration FDA ahead of a multi-centre, randomized trial of the patented Paxman scalp cooling system for the prevention of chemotherapy induced alopecia.

More... (http://www.medicalnewstoday.com/releases/268801.php)